The United States Patent Trial and Appeals Board has invalidated claims New York University (NYU) asserted against ResMed related to the company’s patents, ResMed announced on Tuesday.
In June 2021, NYU filed a complaint for patent infringement against ResMed in the United States District Court, District of Delaware. NYU’s complaint alleged that the AutoSet and AutoRamp features of ResMed’s AirSense 10 AutoSet flow generators infringed one or more claims of seven NYU patents.
ResMed filed petitions with the United States Patent Trial and Appeals Board, asserting that all the claims asserted against ResMed were invalid. In rulings issued from Dec 4 to 7, the United States Patent Trial and Appeals Board judges found that all the challenged claims across the seven patents were invalid.
“At ResMed, we’re committed to providing patients with our leading therapy solutions. Our sustained investment in research and development for over 30 years has culminated in more than 9,500 issued or pending patents and designs,” says Mick Farrell, ResMed’s CEO, in a release. “We applaud the [United States Patent Trial and Appeals Board] ruling and will defend our innovations, ensuring patients continue to receive our therapy solutions, empowering them to live healthier, higher-quality lives.”
Michael Rider, ResMed’s global general counsel and secretary, adds in a release, “We will continue to vigorously defend our innovations. The fact that our intellectual property contributed to this victory is a testament to our investment in research and development, the hard work of our inventors, and the patent protection we pursue to protect our innovation.”
Photo 53292384 © Janpietruszka | Dreamstime.com
